Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic

Adenubiova, E; Arenberger, Petr; Gkalpakioti, Petra; Jirčíková, Jitka; Doležal, Tomáš; Gkalpakiotis, Spyridon

doi:10.1080/09546634.2018.1425358

Cited by 5 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A relatively high number of patients in this real-life study were bio-naïve (38.3%), even though risankizumab is the newest of a number of biologics registered for the treatment of psoriasis. This can be explained by the fact that physicians would prefer to initiate biologic therapy with a known drug demonstrating a high response rate, as it has been shown that patients achieving PASI 100 response have a higher chance of remaining stable during the treatment [14].…”

Section: Discussionmentioning

confidence: 99%

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Gkalpakiotis

Cetkovská

Arenberger

et al. 2021

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction: Risankizumab has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate the effectiveness and safety of risankizumab and its impact on the quality of life of patients with psoriasis in a realworld setting. Methods: We retrospectively analyzed 154 patients from 18 centers in the Czech Republic who had undergone biologic therapy with risankizumab for moderate-to-severe plaque psoriasis. Baseline characteristics included data on comorbidities, demographics, previous therapies, Dermatology Life Quality Index (DLQI) score, and Psoriasis Area and Severity Index (PASI) score. The proportion of patients achieving a 90% improvement in their PASI score from baseline (PASI 90) and complete resolution (PASI 100) after 16, 28, and 52 weeks was analyzed. Results: A total of 95 men and 59 women with mean body mass index (BMI) of 29.6 were enrolled in our analysis. The mean age of the patients was 48.5 years and the mean time from diagnosis until initiation of risankizumab therapy was 22.5 years. After 16 weeks, 63.8 and 44.7% patients achieved PASI 90 and PASI 100 responses, respectively. Improvement continued with time, and the proportion of patients with PASI 90 and PASI 100 responses increased to 82.4 and 67.6%, respectively, at week 52. A significant reduction was observed over time in the DLQI. Patients achieving PASI 100 response at week 16 had a higher reduction in the DLQI score than those with PASI 90 response (-15.9 vs. -11.8). PASI 90 and PASI 100 responses were independent of the BMI and previous biologic therapy. No new safety issues were identified. Conclusions: In this patient population, risankizumab was effective and safe in a real-world setting, and a high number of patients achieved PASI 90 and PASI 100 responses. A higher reduction in the DLQI was seen in patients withThe members of the BIOREP study group are listed in Acknowledgements.

show abstract

Section: Discussionmentioning

confidence: 99%

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Gkalpakiotis

Cetkovská

Arenberger

et al. 2021

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

show abstract

“…The percentage of biologic-naïve patients in our study was quite high (48.2%). This can be explained by the fact that physicians would prefer to initiate biologic therapy with a drug showing a high response rate [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic

Gkalpakiotis,

Kojanová,

Fialová

et al. 2023

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease. Despite the availability of several therapies, many patients affected by this disease remain untreated, do not have adequate response, or suffer from treatment-related toxic effects. It has been shown that the interleukin (IL)-17 pathway plays a key role in the immunopathogenesis of psoriasis. Brodalumab, the first human monoclonal IgG2 antibody that selectively binds to subunit A of the human IL-17 receptor, blocking interactions with a number of cytokines of the IL-17 family, has confirmed fast onset of action, high complete clearance rates, and sustained efficacy. Nevertheless, there is only a limited amount of published real-world evidence (RWE) data. Methods This was an open-label, multicenter, real-world, prospective, non-interventional, non-controlled (single-arm) observational study (LIBERO-CZ) assessing the management of moderate to severe psoriasis with brodalumab in daily practice for up to 52 weeks of treatment. Results Fifty-four patients (70.4% male, mean age 46.9 ± 13.4 years, weight 95.6 ± 22.7 kg, disease duration 18.6 ± 12.7 years) were enrolled and included in the final analysis. Forty-nine of the patients completed the study and five discontinued prematurely; 51.8% of all the enrolled patients were biologic-naïve. At baseline, 28% patients were classified as severe (psoriasis area severity index (PASI) ≥ 20). Overall, the mean PASI decreased by 15.6 from 16.1 (± 5.0) at baseline to 0.5 (± 1.2) at the last visit. The primary endpoint of an absolute PASI ≤ 3 at week 12 (as observed analysis) was achieved by 95.9% of patients. The static Physician’s Global Assessment (sPGA) success (defined as clear = 0 and almost clear = 1) at week 52 was achieved by 92.1% of patients. PASI 75, PASI 90, and PASI 100 were achieved by 98.0%, 87.8%, and 75.5% of patients, respectively, after approximately 52 weeks of treatment. The study also recorded very positive results concerning patient-reported outcomes. Conclusions LIBERO-CZ confirms the fast onset and high clearance rates of brodalumab in real life in both biologic-naïve and biologic-experienced patients.

show abstract

“…Обсуждение. В клинической практике подтверждены эффективность и безопасность АДА у пациентов с псориазом и ПсА в долгосрочной перспективе [29][30][31]. Согласно результатам одноцентрового ретроспективного 9-летнего наблюдательного исследования с участием 316 пациентов (117 с псориазом и 199 с ПсА), частота ответа по индексам PASI75, PASI90, PASI100 к 12-й неделе терапии составила 65,1; 54,5 и 42,9%, а через год лечения -69,7; 62,2 и 44,4% соответственно, ответ на терапию сохранялся в течение всего периода наблюдения.…”

Section: нед подкожно после 3-й инъекции было достигнуто 50% улучшение по индексу Pasi уменьшение выраженности боли в суставах после 8-й unclassified

A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy

Руднева

Natarova

Sorotskaya

et al. 2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

The article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore skin pigmentation. The use of adalimumab for 6 years in a patient suffering from psoriasis, psoriatic arthritis (PsA), vitiligo and autoimmune thyroiditis made it possible to control the activity of psoriasis and PsA, and also contributed to the regression of depigmentation foci. The use of biologic disease-modifying antirheumatic drug therapy in this group of patients in order to achieve repigmentation may be promising.

show abstract

Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic

Abstract: Adalimumab is effective and safe in the long-term treatment of psoriatic patients in daily clinical practice. Once patients achieved PASI100, they tended to remain stable in treatment.

Cited by 5 publications

References 18 publications

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic

A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy

Contact Info

Product

Resources

About